<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403051</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5280</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT01403051</nct_id>
  </id_info>
  <brief_title>High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was done with people who were infected with HIV and needed to start treatment for
      their HIV disease. The purpose of this study is to see if taking vitamin D and calcium will
      help prevent the bone loss that sometimes happens when people start HIV treatment. For this
      study, the following HIV treatment (or HAART) were provided in the form of a single tablet
      that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF). These
      drugs are approved by the FDA to treat HIV infection. The HIV treatment provided is common
      for people who are taking HIV drugs for the first time. The risks seen with this HIV
      treatment are the same that you would encounter when taking these drugs outside of the study.
      The lists of risks of this HIV treatment are included in this document because the drugs are
      provided by the study, not because the drugs are being tested. The purpose of the study is
      only to look at the impact of high doses of vitamin D and calcium in preventing bone loss.
      There are no study objectives related to HIV treatment (EFV/FTC/TDF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip</measure>
    <time_frame>Weeks 0 and 48</time_frame>
    <description>The efficacy endpoint is the percent change from baseline to week 48 in bone mineral density (BMD) at total hip (as measured by DXA scan)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percent Change From Baseline in Bone Mineral Density (BMD) at Spine</measure>
    <time_frame>Weeks 0 and 48</time_frame>
    <description>The percent change from baseline to week 48 in bone mineral density (BMD) at spine as measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Primary Adverse Events</measure>
    <time_frame>From first study treatment to week 48</time_frame>
    <description>Primary adverse events include all SAEs defined according to ICH guidelines and targeted protocol events, which include all diagnoses of hypercalcemia, hypophoatemia, and nephrolithiasis as well as signs and symptoms grade 2 or higher that may be associated with hypercalcemia and all laboratory toxicities grade 2 or higher defined by the 2004 DAIDS grading table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Total 25-OH Vitamin D Level From Baseline to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24, and 48</time_frame>
    <description>Changes in total 25-OH vitamin D from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Total 25-OH vitamin D is the sum of vitamin 25-OH D2 and D3 levels. All 25-OH vitamin D2 or D3 values below the lower limit of 1.25 ng/mL were imputed to 0 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in IL-6 to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Interleukin 6 (IL-6) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in sCD14 to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Soluble cluster of differentiation 14 (sCD14) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in P1NP to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>P1NP (marker of bone formation) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in CTX to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>CTX (marker of bone resorption) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in HOMA-IR to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Homeostatic model assessment insulin resistance (HOMA-IR) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in Fasting Total Cholesterol to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Fasting total cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in Fasting LDL to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Fasting LDL cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in Urinary Phosphate Excretion to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>Fractional excretion of phosphate changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Fractional Excretion of Phosphate (in %) is defined as:
[Urine Phosphate x Serum Creatinine] / [Urine Creatinine x Serum Phosphate] x 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in CD4 to Weeks 4, 12, 24 and 48</measure>
    <time_frame>Weeks 0, 4, 12, 24 and 48</time_frame>
    <description>Total CD4 count changes from baseline to weeks 4, 12, 24 and 48 [week 4/12/24/48 - baseline].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes From Baseline in iPTH to Weeks 24 and 48</measure>
    <time_frame>Weeks 0, 24 and 48</time_frame>
    <description>iPTH (Parathyroid Hormone, intact) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF</intervention_name>
    <description>FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
    <arm_group_label>Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate</arm_group_label>
    <arm_group_label>Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo</arm_group_label>
    <other_name>Atripla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.</description>
    <arm_group_label>Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.</description>
    <arm_group_label>Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for calcium carbonate</intervention_name>
    <description>A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks</description>
    <arm_group_label>Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for vitamin D3</intervention_name>
    <description>A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.</description>
    <arm_group_label>Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  No evidence of any exclusionary resistance mutations based on results from any
             genotype assay from any laboratory that has a CLIA (Clinical Laboratory Improvement
             Amendments) certification or its equivalent. Results must be available from testing
             any time in the past or must be obtained prior to entry and reviewed by the site
             investigator.

          -  ARV drug-na√Øve (&lt;=10 days of ART at any time prior to entry) and no ARV drugs taken
             within the past 30 days.

          -  CD4+ cell count of any value obtained within 90 days prior to study entry at any
             laboratory that has a CLIA certification or its equivalent.

          -  HIV-1 RNA &gt;1000 copies/mL obtained within 90 days prior to study entry at any
             laboratory that has a CLIA certification or its equivalent.

          -  Certain laboratory values obtained within 30 days prior to entry (as indicated in
             section 4.1.6 of the protocol.

          -  Serum calcium &lt; 10.5 mg/dL within 30 days prior to entry.

          -  For women of reproductive potential, negative serum or urine pregnancy test within 48
             hours prior to initiating study medications.

          -  Subjects must refrain from participating in a conception process (i.e., active attempt
             to become pregnant or to impregnate, sperm donation, in vitro fertilization) and if
             participating in sexual activity that could lead to pregnancy, the subject/partner
             must use at least two of the reliable forms of contraceptive listed in section 4.1.9
             of the protocol.

          -  25-OH vitamin D &gt;=10 ng/mL and &lt;75 ng/mL.

          -  Ability and willingness of subject or legally authorized representative to provide
             informed consent.

        Exclusion Criteria:

          -  Current or prior use of bisphosphonate therapy.

          -  Use of vitamin D supplements greater than 800 IU/day within 30 days prior to entry.

          -  Use of calcium supplements greater than 500 mg/day within 30 days prior to entry.

          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or
             their formulations.

          -  Any oral, intravenous, or inhaled steroids within the 30 days prior to
             enrollment(intranasal steroid use is allowed).

          -  Use of androgenic hormones or growth hormones.

          -  Receipt of systemic cytotoxic chemotherapy within 30 days prior to entry.

          -  Pregnancy or currently breastfeeding.

          -  Documentation of acute opportunistic infections within 30 days prior to entry.

          -  Serious illness requiring systemic treatment and/or hospitalization until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 7 days prior to entry.

          -  Weight &gt;300 lbs (exceeds weight limit of DXA scanners).

          -  History of nephrolithiasis (kidney stones).

          -  History of osteoporosis (as documented by DXA scan) or fragility fracture.

          -  Clinically active thyroid disease (use of thyroid hormone replacement therapy
             permitted but TSH must be in normal range).

          -  Current imprisonment or involuntary incarceration in a medical facility for
             psychiatric illness.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Any condition that, in the opinion of the site investigator, would compromise the
             subject's ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar (Turner) Overton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alabama Therapeutics CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael T Yin, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>HIV Prevention &amp; Treatment CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS (5801)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc Crs (1201)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS (601)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS (501)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs (701)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs (801)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS (603)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS (6101)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University CRS (GU CRS) (1008)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Ctr. CRS (5802)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS (2701)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center (2702)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS (4651)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ACTG CRS (101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. ACTG CRS (107)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS (103)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University CRS (2101)</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. Ctr. CRS (31469)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell CRS (7804)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS (401)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS (30329)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Care CRS (1108)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester ACTG CRS (1101)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs (3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Adult CRS (1601)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for Infectious Disease, Wendover Medical Center CRS (3203)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS (2401)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS (2501)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS (2503)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS (2301)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS (6201)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh CRS (1001)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS (2951)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics CRS (3652)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS (31443)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS (31473)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS (1401)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS (5401)</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <results_first_submitted>February 5, 2014</results_first_submitted>
  <results_first_submitted_qc>February 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2014</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A5280 opened under version 1.0 on September 15, 2011, and the first subject was randomized on September 26, 2011. Accrual to the study closed on March 2, 2012, with a total of 167 subjects enrolled from 39 sites within the US.</recruitment_details>
      <pre_assignment_details>Subjects were randomized with a 1:1 ratio at enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
          <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
          <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes only subjects who did not have eligibility violations</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
          <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
          <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="28" upper_limit="47"/>
                    <measurement group_id="B2" value="31" lower_limit="25" upper_limit="44"/>
                    <measurement group_id="B3" value="33" lower_limit="26" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Regardless of Race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian, Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA level</title>
          <description>Entry HIV-RNA level (log10 copies/mL)</description>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" lower_limit="4.1" upper_limit="5.1"/>
                    <measurement group_id="B2" value="4.5" lower_limit="4.0" upper_limit="5.1"/>
                    <measurement group_id="B3" value="4.5" lower_limit="4.1" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count</title>
          <description>Entry total CD4 count (cells/mm3)</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339" lower_limit="230" upper_limit="500"/>
                    <measurement group_id="B2" value="342" lower_limit="232" upper_limit="454"/>
                    <measurement group_id="B3" value="341" lower_limit="230" upper_limit="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip</title>
        <description>The efficacy endpoint is the percent change from baseline to week 48 in bone mineral density (BMD) at total hip (as measured by DXA scan)</description>
        <time_frame>Weeks 0 and 48</time_frame>
        <population>The primary analysis is intent-to-treat (ITT) which is limited to eligible subjects who have baseline and week 48 follow-up regardless of treatment change or discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip</title>
          <description>The efficacy endpoint is the percent change from baseline to week 48 in bone mineral density (BMD) at total hip (as measured by DXA scan)</description>
          <population>The primary analysis is intent-to-treat (ITT) which is limited to eligible subjects who have baseline and week 48 follow-up regardless of treatment change or discontinuation.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" lower_limit="-3.16" upper_limit="-0.40"/>
                    <measurement group_id="O2" value="-3.19" lower_limit="-5.12" upper_limit="-1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was sized to have 80% power to detect a 2 % difference in BMD of the hip from baseline to week 48.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>2-sided test with type I error rate of 5%, not adjusted for multiple comparisons.</p_value_desc>
            <method>Stratified Wilcoxon rank sum test</method>
            <method_desc>Stratified Wilcoxon rank sum test for differences between the two treatment groups, stratified by the screening 25-OH vitamin (&lt;=20 vs. &gt;20 ng/mL)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change From Baseline in Bone Mineral Density (BMD) at Spine</title>
        <description>The percent change from baseline to week 48 in bone mineral density (BMD) at spine as measured by DXA scan</description>
        <time_frame>Weeks 0 and 48</time_frame>
        <population>This analysis is intent-to-treat (ITT) which is limited to eligible subjects who have baseline and week 48 follow-up regardless of treatment change or discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change From Baseline in Bone Mineral Density (BMD) at Spine</title>
          <description>The percent change from baseline to week 48 in bone mineral density (BMD) at spine as measured by DXA scan</description>
          <population>This analysis is intent-to-treat (ITT) which is limited to eligible subjects who have baseline and week 48 follow-up regardless of treatment change or discontinuation.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" lower_limit="-3.78" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-2.91" lower_limit="-4.84" upper_limit="-1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Primary Adverse Events</title>
        <description>Primary adverse events include all SAEs defined according to ICH guidelines and targeted protocol events, which include all diagnoses of hypercalcemia, hypophoatemia, and nephrolithiasis as well as signs and symptoms grade 2 or higher that may be associated with hypercalcemia and all laboratory toxicities grade 2 or higher defined by the 2004 DAIDS grading table</description>
        <time_frame>From first study treatment to week 48</time_frame>
        <population>All enrolled subjects including subjects excluded from efficacy analysis due to eligibility violation.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Adverse Events</title>
          <description>Primary adverse events include all SAEs defined according to ICH guidelines and targeted protocol events, which include all diagnoses of hypercalcemia, hypophoatemia, and nephrolithiasis as well as signs and symptoms grade 2 or higher that may be associated with hypercalcemia and all laboratory toxicities grade 2 or higher defined by the 2004 DAIDS grading table</description>
          <population>All enrolled subjects including subjects excluded from efficacy analysis due to eligibility violation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Total 25-OH Vitamin D Level From Baseline to Weeks 24 and 48</title>
        <description>Changes in total 25-OH vitamin D from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Total 25-OH vitamin D is the sum of vitamin 25-OH D2 and D3 levels. All 25-OH vitamin D2 or D3 values below the lower limit of 1.25 ng/mL were imputed to 0 ng/mL</description>
        <time_frame>Weeks 0, 24, and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=71 and 74 for changes at week 24, n=65 and 68 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Total 25-OH Vitamin D Level From Baseline to Weeks 24 and 48</title>
          <description>Changes in total 25-OH vitamin D from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Total 25-OH vitamin D is the sum of vitamin 25-OH D2 and D3 levels. All 25-OH vitamin D2 or D3 values below the lower limit of 1.25 ng/mL were imputed to 0 ng/mL</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=71 and 74 for changes at week 24, n=65 and 68 for changes at week 48.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="15.0" upper_limit="38.0"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-5.9" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" lower_limit="14.3" upper_limit="35.8"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-6.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in IL-6 to Weeks 24 and 48</title>
        <description>Interleukin 6 (IL-6) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=66 and 68 for changes at week 24, n=58 and 62 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in IL-6 to Weeks 24 and 48</title>
          <description>Interleukin 6 (IL-6) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=66 and 68 for changes at week 24, n=58 and 62 for changes at week 48.</population>
          <units>log10 pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.23" upper_limit="0.11"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.23" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.24" upper_limit="0.12"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.23" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in sCD14 to Weeks 24 and 48</title>
        <description>Soluble cluster of differentiation 14 (sCD14) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=68 and 68 for changes at week 24, n=62 and 63 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in sCD14 to Weeks 24 and 48</title>
          <description>Soluble cluster of differentiation 14 (sCD14) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=68 and 68 for changes at week 24, n=62 and 63 for changes at week 48.</population>
          <units>log10 ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.08" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.07" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.05" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.06" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in P1NP to Weeks 24 and 48</title>
        <description>P1NP (marker of bone formation) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in P1NP to Weeks 24 and 48</title>
          <description>P1NP (marker of bone formation) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="2" upper_limit="26"/>
                    <measurement group_id="O2" value="21" lower_limit="12" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0" upper_limit="29"/>
                    <measurement group_id="O2" value="18" lower_limit="7" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in CTX to Weeks 24 and 48</title>
        <description>CTX (marker of bone resorption) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in CTX to Weeks 24 and 48</title>
          <description>CTX (marker of bone resorption) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-0.01" upper_limit="0.27"/>
                    <measurement group_id="O2" value="0.22" lower_limit="0.11" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.04" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.05" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in HOMA-IR to Weeks 24 and 48</title>
        <description>Homeostatic model assessment insulin resistance (HOMA-IR) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=69 and 73 for changes at week 24, n=64 and 69 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in HOMA-IR to Weeks 24 and 48</title>
          <description>Homeostatic model assessment insulin resistance (HOMA-IR) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=69 and 73 for changes at week 24, n=64 and 69 for changes at week 48.</population>
          <units>HOMA-IR</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="-0.21" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.39" lower_limit="-0.11" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="-0.26" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.26" lower_limit="-0.44" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in Fasting Total Cholesterol to Weeks 24 and 48</title>
        <description>Fasting total cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=74 and 80 for changes at week 24, n=68 and 73 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in Fasting Total Cholesterol to Weeks 24 and 48</title>
          <description>Fasting total cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=74 and 80 for changes at week 24, n=68 and 73 for changes at week 48.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="-4" upper_limit="29"/>
                    <measurement group_id="O2" value="18" lower_limit="1" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="-6" upper_limit="28"/>
                    <measurement group_id="O2" value="14" lower_limit="-1" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in Fasting LDL to Weeks 24 and 48</title>
        <description>Fasting LDL cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=70 and 72 for changes at week 24, n=65 and 67 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in Fasting LDL to Weeks 24 and 48</title>
          <description>Fasting LDL cholesterol changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=70 and 72 for changes at week 24, n=65 and 67 for changes at week 48.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-10" upper_limit="17"/>
                    <measurement group_id="O2" value="8" lower_limit="-11" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-9" upper_limit="14"/>
                    <measurement group_id="O2" value="4" lower_limit="-14" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in Urinary Phosphate Excretion to Weeks 24 and 48</title>
        <description>Fractional excretion of phosphate changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Fractional Excretion of Phosphate (in %) is defined as:
[Urine Phosphate x Serum Creatinine] / [Urine Creatinine x Serum Phosphate] x 100%</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=58 and 70 for changes at week 24, n=59 and 69 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in Urinary Phosphate Excretion to Weeks 24 and 48</title>
          <description>Fractional excretion of phosphate changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).
Fractional Excretion of Phosphate (in %) is defined as:
[Urine Phosphate x Serum Creatinine] / [Urine Creatinine x Serum Phosphate] x 100%</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=58 and 70 for changes at week 24, n=59 and 69 for changes at week 48.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-2.4" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.8" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.8" upper_limit="3.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-1.9" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in CD4 to Weeks 4, 12, 24 and 48</title>
        <description>Total CD4 count changes from baseline to weeks 4, 12, 24 and 48 [week 4/12/24/48 - baseline].</description>
        <time_frame>Weeks 0, 4, 12, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=78 and 86 for changes at week 4, n=77 and 85 for changes at week 4, n=76 and 84 for changes at week 24, n=69 and 80 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in CD4 to Weeks 4, 12, 24 and 48</title>
          <description>Total CD4 count changes from baseline to weeks 4, 12, 24 and 48 [week 4/12/24/48 - baseline].</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=78 and 86 for changes at week 4, n=77 and 85 for changes at week 4, n=76 and 84 for changes at week 24, n=69 and 80 for changes at week 48.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="2" upper_limit="146"/>
                    <measurement group_id="O2" value="60" lower_limit="15" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" lower_limit="41" upper_limit="170"/>
                    <measurement group_id="O2" value="106" lower_limit="60" upper_limit="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="46" upper_limit="195"/>
                    <measurement group_id="O2" value="136" lower_limit="66" upper_limit="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" lower_limit="113" upper_limit="305"/>
                    <measurement group_id="O2" value="201" lower_limit="108" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes From Baseline in iPTH to Weeks 24 and 48</title>
        <description>iPTH (Parathyroid Hormone, intact) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
        <time_frame>Weeks 0, 24 and 48</time_frame>
        <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
            <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
            <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla)
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes From Baseline in iPTH to Weeks 24 and 48</title>
          <description>iPTH (Parathyroid Hormone, intact) changes from baseline to weeks 24 and 48 ( [week 24-baseline] and [week 48 - baseline], respectively).</description>
          <population>Included all available data regardless of treatment change/discontinuation, but was limited to eligible subjects who had both baseline and follow-up data.
n=72 and 77 for changes at week 24, n=66 and 72 for changes at week 48.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-3.8" upper_limit="5.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="-0.8" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-4.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="5.2" lower_limit="-0.7" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study treatment to week 48</time_frame>
      <desc>Adverse events from patients' first study treatment date to off study date.
medDRA version 16.1</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Vitamin D3 and Calcium Carbonate Plus EFV/FTC/TDF</title>
          <description>The participants were administered vitamin D3, calcium carbonate and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Vitamin D3: One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
Calcium Carbonate: Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Vitamin D3 Placebo and Calcium Placebo Plus EFV/FTC/TDF</title>
          <description>The participants were administered a placebo for vitamin D3, a placebo for calcium carbonate, and FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla).
Placebo for vitamin D3: A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
Placebo for calcium carbonate: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Atripla: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>617-432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

